Botulinum toxin type b
NeuroBloc (botulinum toxin type b) is an unknown pharmaceutical. Botulinum toxin type b was first approved as Neurobloc on 2001-01-22. It is used to treat sialorrhea in the USA. It has been approved in Europe to treat torticollis.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daxxify | Biologic Licensing Application | 2023-03-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sialorrhea | HP_0002307 | D012798 | K11.7 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | 1 | 1 | 3 |
| Torticollis | D014103 | HP_0000473 | F45.8 | — | 2 | — | 1 | — | 3 |
| Neoplasms | D009369 | C80 | — | — | — | 1 | — | 1 | |
| Wounds and injuries | D014947 | T14.8 | — | — | — | 1 | — | 1 | |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | 1 | |
| Brain injuries | D001930 | S06.9 | — | — | — | 1 | — | 1 | |
| Dystonic disorders | D020821 | G24 | — | — | — | 1 | — | 1 | |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 2 | 4 | — | — | 5 |
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | — | — | 2 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 1 |
| Traumatic brain injuries | D000070642 | S06 | — | 1 | 1 | — | — | 1 | |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Hyperhidrosis | D006945 | HP_0000975 | — | 1 | — | — | — | 1 | |
| Abdominal hernia | D046449 | K46 | — | 1 | — | — | — | 1 | |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BOTULINUM TOXIN TYPE B |
| INN | — |
| Description | Myobloc, NeuroBloc (botulinum toxin type b) is an neurotoxin pharmaceutical. Botulinum toxin type b was first approved as Myobloc on 2001-01-22. It is used to treat sialorrhea in the USA. It has been approved in Europe to treat torticollis. |
| Classification | Neurotoxin |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201569 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 522 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
46,762 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more